Merck delivered a clean Q1 2026 operational beat on April 30, with revenue of 16.3 billion dollars growing 5 percent year over year and Keytruda sales rising 12 percent to 8.0 billion dollars.
MRK
· Healthcare · Drug Manufacturers - General
· Market cap $282.23B
QuantHub Original Research · Updated 2026-05-20
·
High QualityHigh quality business beating near term estimates, but 2028 Keytruda loss of exclusivity caps upside and shares already reflect most of the post Q1 optimism with roughly 3 percent upside to fair value.Fair Value
MRK is trading near fair value. No urgent action needed.
QuantHub Research: Investment Thesis
Maturing Phase
Merck delivered a clean Q1 2026 operational beat on April 30, with revenue of 16.3 billion dollars growing 5 percent year over year and Keytruda sales rising 12 percent to 8.0 billion dollars. The reported loss of 1.28 dollars per share, though better than the negative 1.47 dollar consensus estimate, reflected a 3.62 dollar per share IPR and D charge tied to the Cidara Therapeutics acquisition and is not a signal of operating deterioration. Management raised the 2026 revenue outlook to 65.8 to 67 billion dollars and adjusted EPS to 5.04 to 5.16 dollars. The stock has rebounded sharply from 2025 lows on Winrevair traction, the Verona Pharma acquisition, and growing investor confidence in the post Keytruda strategy. However, the central investment debate remains unchanged: Keytruda still accounts for roughly half of pharmaceutical sales and faces United States patent loss of exclusivity in 2028. Gardasil continues to struggle with the suspension of China shipments and the wind down of the Japan catch up program. At 114 dollars the shares trade at roughly 22 times forward guidance, which leaves limited margin of safety against the 2028 cliff unless the subcutaneous Keytruda Qlex conversion, Winrevair ramp, Verona Ohtuvayre, and the enlicitide oral PCSK9 launch collectively replace meaningful Keytruda revenue.
Merck has rerated meaningfully from 75 dollars a year ago to 114 dollars as Keytruda growth, Winrevair traction, and the Verona deal restored confidence, but valuation is now full at roughly 22 times forward guidance with the 2028 patent cliff approaching. The last month analyst price target average of 112 dollars sits below the current price, while the trailing twelve month average target of 122 dollars implies modest upside. The shares price in operational execution but not in any cushion against the post 2028 revenue gap.
12–18 Month Outlook
The next 18 months are a transition window for Merck dominated by the approaching 2028 Keytruda patent cliff. In the near term the company should continue posting mid single digit revenue growth driven by Keytruda volume gains, Keytruda Qlex subcutaneous launch traction, Winrevair ramp now annualizing above 2 billion dollars, and the recently acquired Verona Pharma Ohtuvayre franchise. Enlicitide oral PCSK9 could launch late in this window and offer optionality. Offsetting these tailwinds are the continued Gardasil decline from the China shutdown and Japan catch up rolloff, ongoing IPR and D charges from the Cidara and Terns deals, and the steady erosion of generic and biosimilar exposed products. With shares already trading at roughly 22 times forward guidance the market has largely priced in operational execution. The dominant overhang remains 2028, when United States Keytruda patent loss of exclusivity is expected to drive a 10 to 20 percent franchise decline initially with more severe erosion possible if Keytruda Qlex conversion underwhelms. Realistically the stock is likely to trade in a 100 to 130 dollar range over the next 18 months with upside dependent on Qlex subcutaneous adoption data and downside risk if pipeline readouts disappoint. Investors should expect modest total returns with most of the upside captured by the recent rerating from 2025 lows.
Bull vs Bear
Bull Case
Keytruda grew 12 percent reported in Q1 2026 to 8.0 billion dollars, demonstrating durable franchise momentum heading into the loss of exclusivity window.
Keytruda Qlex subcutaneous formulation is targeting 30 to 40 percent patient conversion ahead of biosimilar entry, which would extend the franchise tail well past the 2028 loss of exclusivity.
Winrevair sales reached 525 million dollars in Q1, up 88 percent year over year, validating the Acceleron acquisition and providing a multi billion dollar growth engine.
Management raised both ends of the 2026 guidance range for revenue and adjusted EPS, signaling confidence in the underlying base business.
The Verona Pharma acquisition adds Ohtuvayre for COPD maintenance with peak sales potential of 3 to 4 billion dollars and a patent runway into the mid 2030s, directly addressing the post Keytruda revenue gap.
Enlicitide, the oral PCSK9 inhibitor, has received an FDA priority voucher and could launch into a large LDL lowering market starting in 2026.
Bear Case
Keytruda accounts for roughly half of Merck pharmaceutical revenue and loses United States patent exclusivity in 2028, creating a multi billion dollar revenue cliff that pipeline assets will struggle to fully offset.
Analyst projections suggest Keytruda sales could decline 10 to 20 percent in the years immediately following loss of exclusivity, with steeper erosion possible if subcutaneous conversion falls short of the 30 to 40 percent target.
Gardasil is in structural decline, with Merck having halted China shipments in February 2026 and the Japan catch up program rolling off, removing a key vaccine growth pillar.
Q1 reported a 3.62 dollar per share IPR and D charge from the Cidara deal and the pending Terns Pharmaceuticals transaction will trigger an additional 2.35 dollar per share charge in Q2, reflecting an active and dilutive M and A strategy with uncertain returns.
Forward valuation of roughly 22 times the 5.10 dollar adjusted EPS midpoint is full given the imminent patent cliff and leaves little room for pipeline disappointment.
Enlicitide faces fasting requirement limitations that AstraZeneca's competing oral PCSK9 program is attempting to undercut, capping commercial upside.
Leadership & Competitive Position
Robert M. Davis
Tenure5 yrs
Beats guidance80% of qtrs
Capital allocationGood
Robert Davis has been CEO since July 2021 and has steered Merck through Keytruda peak earnings while preparing for the 2028 patent cliff. Under his leadership Merck completed the Acceleron acquisition that brought Winrevair, the Prometheus Biosciences deal, the Verona Pharma transaction adding Ohtuvayre, and the pending Cidara and Terns Pharmaceuticals acquisitions. The Q1 2026 outperformance and the raised guidance demonstrate operational discipline, though the cadence of dilutive IPR and D charges suggests aggressive but expensive pipeline building.
Competitive Moat
narrowing
intangible assetsbrandcost advantage
Keytruda remains the dominant PD-1 immunotherapy with leadership across multiple solid tumor indications, but the 2028 loss of exclusivity will erode this position. Winrevair has secured first mover advantage in activin signaling inhibition for pulmonary arterial hypertension. Vaccines face headwinds from Gardasil China and Japan declines while RotaTeq and Vaxneuvance hold steady. Animal Health remains a steady contributor.
Competitors: Bristol Myers Squibb (BMY), Pfizer (PFE), AstraZeneca (AZN), Johnson & Johnson (JNJ)
Disruption: High given the 2028 Keytruda loss of exclusivity and the likely emergence of PD-1 biosimilars and next generation immuno oncology combinations from competitors.
QuantHub Research
Valuation
Multiple
Current
Median 3yr
Median 5yr
Min 5yr
Max 5yr
P/E
22.4x
14.5x
13.2x
6.65x
32.19x
P/S
4.33x
4.65x
4.55x
3.2x
5.96x
P/FCF
20.2x
16.0x
13.5x
5.1x
142.8x
P/S 4.33x vs 5yr range 3.2-5.96x sits near median 4.55x, while forward P/E of 22.4x is elevated versus the 5yr median of 13.2x but reasonable given the Keytruda Qlex transition story.
Will include the Terns Pharmaceuticals acquisition charge of approximately 2.35 dollars per share and provide an updated guidance read on Keytruda Qlex subcutaneous adoption trends.
high
2026-Q3
Keytruda Qlex Subcutaneous Conversion Data
Early adoption metrics for the subcutaneous formulation are the single most important variable for modeling post 2028 Keytruda franchise economics.
high
2026-Q4
Enlicitide Oral PCSK9 FDA Decision
Potential approval and launch of the first oral PCSK9 inhibitor into a large LDL lowering market.
medium
2026-10-29
Q3 2026 Earnings Release
Consensus calls for 2.29 dollars EPS on 17.35 billion dollars revenue, a key read on second half momentum.
medium
2028-Q3
Keytruda United States Loss of Exclusivity
The single largest revenue cliff in pharmaceutical industry history with Keytruda generating roughly half of pharmaceutical sales. Biosimilar entry expected to erode revenue 10 to 20 percent initially.
high
Risks
Keytruda 2028 Patent Cliff
high
Keytruda represents roughly half of pharmaceutical revenue and faces United States loss of exclusivity in 2028 with biosimilar competition expected to drive a multi billion dollar revenue gap.
Gardasil Structural Headwinds
high
China shipments halted in February 2026 and the Japan catch up program is rolling off, removing a key vaccine growth pillar that previously contributed 8 to 9 billion dollars annually.
Subcutaneous Conversion Execution
high
If Keytruda Qlex fails to achieve the targeted 30 to 40 percent patient conversion ahead of biosimilars the post 2028 revenue erosion will be substantially worse than current estimates.
Dilutive M and A Charges
medium
Cidara, Terns, and Verona transactions have triggered or will trigger meaningful IPR and D charges with uncertain returns on the acquired assets.
Pipeline Execution
medium
Enlicitide faces competitive pressure from AstraZeneca and Winrevair label expansion timing is uncertain, both critical to the post Keytruda revenue base.
Drug Pricing Regulation
medium
Inflation Reduction Act negotiated pricing and broader policy pressure could further compress margins on key products.
Growth Engines
Keytruda Qlex Subcutaneousscaling
Subcutaneous formulation aiming for 30 to 40 percent patient conversion before biosimilar entry, extending franchise economics past 2028 loss of exclusivity.
Winrevair Pulmonary Hypertensionscaling
525 million dollars in Q1 2026 sales growing 88 percent, with consensus peak sales estimates in the multi billion dollar range as label expansions progress.
Verona Ohtuvayre COPDearly
Acquired in 2025 with peak sales potential of 3 to 4 billion dollars and patent runway into the mid 2030s, central to Merck's post Keytruda diversification.
Enlicitide Oral PCSK9early
Oral PCSK9 inhibitor with FDA priority voucher targeting LDL lowering market, potential launch in late 2026 or early 2027.
Animal Healthmature
Steady mid single digit grower anchored by Bravecto and livestock vaccines, providing diversification.
Q1 2026 Earnings Beat with Cidara IPR and D Charge Driving Reported Loss
Revenue of 16.286 billion dollars beat the 15.846 billion dollar estimate and EPS of negative 1.28 dollars beat the negative 1.47 dollar estimate. The reported loss reflected a 3.62 dollar per share charge from the Cidara Therapeutics acquisition rather than operating deterioration. Management raised 2026 revenue guidance to 65.8 to 67 billion dollars and adjusted EPS to 5.04 to 5.16 dollars.
2026-04-30
Keytruda Q1 Sales Reach 8.0 Billion Dollars Up 12 Percent
Keytruda growth was driven by metastatic and earlier stage cancer indications with approximately 250 million dollars from purchase timing in the United States. Keytruda Qlex subcutaneous formulation sales reached 128 million dollars in early launch.
2026-04-30
Winrevair Q1 Sales Reach 525 Million Dollars Up 88 Percent
Validates the Acceleron acquisition thesis and positions Winrevair as a multi billion dollar franchise as label expansions progress.
2026-04-30
Terns Pharmaceuticals Acquisition Pending Close
Expected to close in May with a one time charge of approximately 5.8 billion dollars or 2.35 dollars per share for the CML drug program.
2026-02-15
Gardasil China Shipments Halted
Merck announced suspension of Gardasil shipments to China citing soft demand, removing a previously material vaccine revenue contributor.
2025-Q4
Verona Pharma Acquisition Closed
Approximately 10 billion dollar deal adds Ohtuvayre for COPD maintenance with peak sales potential of 3 to 4 billion dollars and patent protection into the mid 2030s, addressing the post Keytruda revenue gap.
This is AI-powered fundamental analysis built from scratch — not aggregated analyst ratings. Get this research for your entire portfolio plus daily briefings, research signals, and options income.
QuantHub research is focused on quality businesses with durable competitive advantages — companies we'd want to own for 3–5 years or more. We are not short-term traders. Every analysis is built around a single question: is this a great business available at a reasonable price for a long-term investor?
We start where most analysts finish: the fundamentals. For every company, our AI ingests years of financial statements — revenue, margins, free cash flow, and how the business has been valued by the market across multiple cycles. But numbers alone don't tell you whether a business is worth owning.
The harder work is qualitative. We assess the competitive moat: is it widening or eroding? We read the leadership track record — how capital has been allocated, whether management has earned trust through consistent execution. We look at what the market is afraid of, and whether that fear is priced in fairly or irrationally.
Valuation is always relative. A stock is cheap or expensive compared to its own history. We build scenario matrices anchored to 5-year historical multiples, then ask: what has to go right for the upside case, and what's the floor if it doesn't?
Finally, we write an 18-month forward outlook — not a price target, but a mental model of where this business will be and what the narrative will look like. Every note is dated and versioned. When material facts change, we update the thesis.
Frequently Asked Questions
Is MRK undervalued?
MRK is currently fairly valued at $119.60 vs. our fair value estimate of $118.00 (-1% upside).
What is MRK's fair value?
QuantHub Research estimates MRK's fair value at $118.00 based on our proprietary valuation model incorporating historical P/S, P/E, and P/FCF multiples over a 5-year range.
What are the key risks for MRK?
Keytruda 2028 Patent Cliff: Keytruda represents roughly half of pharmaceutical revenue and faces United States loss of exclusivity in 2028 with biosimilar competition expected to drive a multi billion dollar revenue gap. Gardasil Structural Headwinds: China shipments halted in February 2026 and the Japan catch up program is rolling off, removing a key vaccine growth pillar that previously contributed 8 to 9 billion dollars annually. Subcutaneous Conversion Execution: If Keytruda Qlex fails to achieve the targeted 30 to 40 percent patient conversion ahead of biosimilars the post 2028 revenue erosion will be substantially worse than current estimates.
What is the bull case for MRK?
Keytruda grew 12 percent reported in Q1 2026 to 8.0 billion dollars, demonstrating durable franchise momentum heading into the loss of exclusivity window. Keytruda Qlex subcutaneous formulation is targeting 30 to 40 percent patient conversion ahead of biosimilar entry, which would extend the franchise tail well past the 2028 loss of exclusivity. Winrevair sales reached 525 million dollars in Q1, up 88 percent year over year, validating the Acceleron acquisition and providing a multi billion doll